Costigliola P, Tumietto F, Ricchi E, Chiodo F
Institute of Infectious Diseases, University of Bologna, Italy.
AIDS. 1992 Oct;6(10):1121-5. doi: 10.1097/00002030-199210000-00009.
To determine the amount of circulating CD4+ cells positive for intracellular p24 antigen during HIV infection, and to correlate the results with clinical, virological and therapeutic parameters.
Data were obtained from 24 anti-HIV-negative subjects (controls) and 47 anti-HIV-positive patients classified according to clinical diagnosis, serum p24-antigen assay results, and antiretroviral treatment with zidovudine, using a modified flow cytometric assay for the detection of intracellular HIV p24 antigen (p24-FCA) in circulating CD4+ lymphocytes.
The proportion of CD4+ lymphocytes positive for p24-FCA correlated well with HIV infection (1.685 +/- 1.902 versus 0.160 +/- 0.152 in controls; P < 0.001) and clinical progression [Centers for Disease Control (CDC) stage II: 1.310 +/- 1.187; CDC stage III 1.145 +/- 1.442; CDC stage IVA/C2: 2.335 +/- 2.112; CDC stage IVC1: 2.066 +/- 2.420]. The percentage of CD4+ cells positive for HIV p24-FCA was inversely correlated with an absolute peripheral blood CD4+ lymphocyte count (Spearman's rank correlation = -0.324; P < 0.05). However, there was no statistically significant difference between patients in presence (n = 27; 1.938 +/- 2.095) or absence (n = 20; 1.343 +/- 1.594) of serum p24 Ag. The variable linked most strongly to the detection of intracellular p24 in anti-HIV-positive patients was zidovudine treatment: the proportion of p24-FCA-positive CD4+ lymphocytes was significantly lower (0.825 +/- 0.910) in the treated patients (n = 25) than in the untreated patients (n = 22; 2.662 +/- 2.248; P < 0.001).
Our results suggest that CD4+ p24 Ag-FCA is a rapid and easy test for the identification of the proportion of CD4+ lymphocytes with intracellular p24 Ag, and that it could be more appropriate than serum p24 Ag assay in evaluating disease progression and efficacy of antiretroviral treatment.
确定HIV感染期间细胞内p24抗原呈阳性的循环CD4 +细胞数量，并将结果与临床、病毒学和治疗参数相关联。
数据来自24名抗HIV阴性受试者（对照组）和47名抗HIV阳性患者，这些患者根据临床诊断、血清p24抗原检测结果以及使用齐多夫定进行抗逆转录病毒治疗进行分类，采用改良的流式细胞术检测循环CD4 +淋巴细胞中的细胞内HIV p24抗原（p24-FCA）。
p24-FCA呈阳性的CD4 +淋巴细胞比例与HIV感染密切相关（对照组为1.685±1.902，而对照组为0.160±0.152；P <0.001）和临床进展[疾病控制中心（CDC）II期：1.310±1.187；CDC III期1.145±1.442；CDC IVA/C2期：2.335±2.112；CDC IVC1期：2.066±2.420]。HIV p24-FCA呈阳性的CD4 +细胞百分比与外周血CD4 +淋巴细胞绝对计数呈负相关（Spearman等级相关性=-0.324；P <0.05）。然而，血清p24 Ag阳性（n = 27；1.938±2.095）或阴性（n = 20；1.343±1.594）的患者之间无统计学显著差异。与抗HIV阳性患者细胞内p24检测最密切相关的变量是齐多夫定治疗：治疗患者（n = 25）中p24-FCA阳性CD4 +淋巴细胞的比例显著低于未治疗患者（n = 22；2.662±2.248；P <0.001）。
我们的结果表明，CD4 + p24 Ag-FCA是一种快速简便的检测方法，可用于鉴定细胞内p24 Ag的CD4 +淋巴细胞比例，并且在评估疾病进展和抗逆转录病毒治疗疗效方面可能比血清p24 Ag检测更合适。
